This review focuses on the clinical evidence on whether individuals with acute myelogenous leukemia (AML) in first remission should undergo an allogeneic hematopoietic cell transplant (HCT) versus receiving post-remission chemotherapy (or both). The authors address four common clinical questions: 1) Do only individuals achieving second remission benefit from a transplant? 2) Is allogeneic HCT the only effective therapy for relapse? 3) Can we accurately predict which individuals with AML in first remission need a transplant? and 4) What is the clinical usefulness of detecting minimal residual disease in patients achieving first remission?
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: HCT for Patients with AML in First Remission
Oct 2014